Accreditation/Credit Designation
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-373-H01-P. The activity is available for CE credit through October 29, 2022.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC, and Pharmacy Times Continuing Education™.
Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for. Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
This CE activity is also offered free online at www.PharmacyTimes.org/go/ IBD-AJMC, where you will be directed to the activity in its entirety, including the online pretest and posttest, activity evaluation, and request for credit.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
Triple-Negative Breast Cancer: Perspectives on the Disparities in Care and Managed Care Considerations for the Advancing Treatment Paradigm
Release Date: October 29, 2021
Expiration Date: October 29, 2022
Activity Overview
Triple-negative breast cancer (TNBC) is aggressive and has the highest rate of metastatic disease and lowest survival rate compared with other breast cancer subtypes. Treatment is challenging due to disease complexity, with available therapies including cytotoxic chemotherapies, PARP inhibitors, immunotherapies, and antibody therapy. There are also disparities to overcome in the treatment of TNBC, as clinical outcomes are impacted by both biologic and nonbiologic factors in various ethnic groups. This activity will explore the clinical data and guideline recommendations for the treatment of TNBC as well as strategies for formulary management. Additionally, panelists will share insights with participants to promote awareness of potential racial disparities in cancer care.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Pharmacists and those seeking pharmacy credits are encouraged to register with our partner, Pharmacy Times Continuing Education (https://www.pharmacytimes.org/) for the online version of this supplement at: https://www.pharmacytimes.org/courses/triple-negative-breast-cancer-perspectives-on-the-disparities-in-care-and-managed-care-considerations-for-the-advancing-treatment-paradigm.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explore the epidemiology and clinical guideline treatment recommendations for triple-negative breast cancer (TNBC) as well as challenges to care
- Investigate clinical data of new and emerging immunotherapies in the treatment of TNBC
- Analyze the impact of racial disparities on treatment outcomes for patients with TNBC as well as strategies to improve access to care
- Identify strategies for managed care professionals to incorporate TNBC therapies into health-system formularies
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Moderator
Manager, Oncology Pharmacy Services
PGY2 Oncology Pharmacy Residency Program Director
Allegheny Health Network
Pittsburgh, Pennsylvania
Disclosures: Danielle Roman, PharmD, BCOP has no relevant financial relationships with ineligible companies.
Faculty
Clinical Pharmacist Specialist, Oncology
University of Michigan - Michigan Medicine
Ann Arbor, Michigan
Disclosures: Allison Schepers, PharmD, BCOP has no relevant financial relationships with ineligible companies.
SVP, Clinical Strategy and Growth
OncoHealth
Plantation, Florida
Clinical Affiliate Assistant Professor
Nova Southeastern University College of Pharmacy
Fort Lauderdale, Florida
Disclosures: Laura R. Bobolts, PharmD, BCOP has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
